Breaking News

ChemDiv Earns Lilly Milestones

December 19, 2012

Identifies multiple active series to supplement Lilly programs

ChemDiv, Inc., a drug discovery and development CRO, has received several milestones across three therapeutic areas under its collaboration with Eli Lilly. Financial details were not disclosed.
Alex Kiselyov, Ph.D., president of ChemDiv, said, "Using our integrated drug discovery platforms, a team of chemists and biologists at ChemDiv identified multiple active series to supplement therapeutic programs at Eli Lilly. This is yet another step in our successful collaborative efforts with pharma and biotech partners to identify advanced preclinical drug candidates."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important